Published in Proc Natl Acad Sci U S A on June 01, 1988
Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: correlation with susceptibility to hepatocarcinogenesis. Proc Natl Acad Sci U S A (1991) 1.08
Activation of the c-Ki-ras oncogene in aflatoxin B1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A (1993) 1.04
Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors. Proc Natl Acad Sci U S A (1990) 1.04
Role of proto-oncogene activation in carcinogenesis. Environ Health Perspect (1992) 0.99
Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer (2001) 0.96
Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma. Br J Cancer (1997) 0.87
Determinants of specificity for aflatoxin B1-8,9-epoxide in alpha-class glutathione S-transferases. Biochem J (1999) 0.82
The genetics of human cancer: implications for ecotoxicology. Environ Health Perspect (1994) 0.79
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet (1982) 54.79
DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells. Proc Natl Acad Sci U S A (1979) 21.22
The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (1981) 8.44
Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature (1986) 6.14
Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. J Virol (1980) 4.63
Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature (1985) 4.40
Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature (1984) 4.38
Some current perspectives on chemical carcinogenesis in humans and experimental animals: Presidential Address. Cancer Res (1978) 3.73
Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals: discussion. Proc Natl Acad Sci U S A (1976) 3.46
Dietary aflatoxins and liver cancer--a population based study in Kenya. Br J Cancer (1973) 2.04
Highly repeated DNA families in the rat. J Biol Chem (1984) 2.02
Characterization of c-Ki-ras oncogene alleles by direct sequencing of enzymatically amplified DNA from carcinogen-induced tumors. Proc Natl Acad Sci U S A (1987) 1.98
Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc Natl Acad Sci U S A (1986) 1.83
Dose-response characteristics of aflatoxin B1 carcinogenesis in the rat. Cancer Res (1967) 1.82
Aflatoxin B -oxide generated by chemical or enzymic oxidation of aflatoxin B1 causes guanine substitution in nucleic acids. Nature (1977) 1.76
Aflatoxin B1-2,3-oxide as a probable intermediate in the covalent binding of aflatoxins B1 and B2 to rat liver DNA and ribosomal RNA in vivo. Cancer Res (1977) 1.67
Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver. Proc Natl Acad Sci U S A (1978) 1.64
Detection and identification of activated oncogenes in spontaneously occurring benign and malignant hepatocellular tumors of the B6C3F1 mouse. Proc Natl Acad Sci U S A (1986) 1.60
Activating mutations of the c-Ha-ras protooncogene in chemically induced hepatomas of the male B6C3 F1 mouse. Proc Natl Acad Sci U S A (1986) 1.47
Frequent activation of c-kis as a transforming gene in fibrosarcomas induced by methylcholanthrene. Science (1983) 1.38
A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. Nucleic Acids Res (1986) 1.33
Activation of N-ras in a human melanoma cell line. Mol Cell Biol (1985) 1.30
Oncogenes and human cancer: cause or consequence? Carcinogenesis (1986) 1.22
Carcinogenesis in rats by aflatoxins B1, G1, and B2. Cancer Res (1969) 1.18
Identification of an activated c-Ki-ras oncogene in rat liver tumors induced by aflatoxin B1. Proc Natl Acad Sci U S A (1986) 1.13
Molecular cloning of an oncogene from a human hepatocellular carcinoma. Proc Natl Acad Sci U S A (1986) 1.03
A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int J Epidemiol (1982) 1.01
gamma-Glutamyltranspeptidase and the ras-induced transformation of a rat liver cell line. Cancer Res (1986) 1.00
Comparison of aflatoxin B1 and aflatoxin G1 binding to cellular macromolecules in vitro, in vivo and after peracid oxidation; characterisation of the major nucleic acid adducts. Chem Biol Interact (1979) 0.98
An examination of the relative resistances to aflatoxin B1 and susceptibilities to gamma-glutamyl p-phenylene diamine mustard of gamma-glutamyl transferase negative and positive cell lines. Carcinogenesis (1981) 0.96
Carcinogen specificity in the activation of transforming genes by direct-acting alkylating agents. Carcinogenesis (1985) 0.96
Effect of formation and removal of aflatoxin B1:DNA adducts in 10T 1/2 mouse embryo fibroblasts on cell viability. Cancer Res (1980) 0.88
Multifactoral etiology of human liver cancer. Carcinogenesis (1984) 0.87
An alternative assay system for the detection of transforming genes. Carcinogenesis (1984) 0.83
A system for transformation of rat liver cells in vitro by acute treatment with aflatoxin. Br J Cancer (1987) 0.81
Identification of human N-ras as the common oncogene in NIH 3T3 cells transformed with DNAs from human primary hepatic cancer and hepatoma 7402 line. Sci Sin B (1986) 0.80
A physical map of 30,000 human genes. Science (1998) 12.43
Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell (1994) 9.73
All ras proteins are polyisoprenylated but only some are palmitoylated. Cell (1989) 9.68
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature (1994) 6.16
A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell (1990) 6.08
Activation of the MAP kinase pathway by the protein kinase raf. Cell (1992) 5.95
Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J (1994) 4.37
The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product. Nature (1988) 4.33
Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J (1995) 4.17
Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. EMBO J (1992) 4.00
Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature (1983) 3.86
Involvement of p21ras in activation of extracellular signal-regulated kinase 2. Nature (1992) 3.78
Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature (1998) 3.67
A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J (1991) 3.64
Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol (1998) 3.58
Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J (1989) 3.51
Normal p21N-ras couples bombesin and other growth factor receptors to inositol phosphate production. Nature (1986) 3.41
Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest (1994) 3.30
EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor. Curr Biol (1994) 3.06
Dynamic fatty acylation of p21N-ras. EMBO J (1987) 2.99
Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci U S A (1988) 2.99
Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature (1985) 2.90
Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol (1995) 2.82
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J (1999) 2.79
Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J (2001) 2.66
A radiation hybrid map of the rat genome containing 5,255 markers. Nat Genet (1999) 2.54
Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J (1995) 2.51
Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem (1997) 2.47
Isolation of dermatan sulfate proteoglycans from mature bovine articular cartilages. J Biol Chem (1985) 2.39
Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr Biol (1998) 2.33
rho family GTPase activating proteins p190, bcr and rhoGAP show distinct specificities in vitro and in vivo. EMBO J (1993) 2.31
Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res (1991) 2.30
DNA in medicine. Oncogenes. Lancet (1984) 2.28
Post-translational modifications of p21rho proteins. J Biol Chem (1992) 2.17
Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J (1991) 2.09
Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst (1977) 2.07
Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science (1998) 2.06
Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene (2006) 2.03
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol (2007) 1.96
Increasing prevalence of asthma diagnosis and symptoms in children is confined to mild symptoms. Thorax (2001) 1.95
Mesoderm induction in Xenopus caused by activation of MAP kinase. Nature (1995) 1.86
Lysophosphatidic acid stimulates mitogen-activated protein kinase activation via a G-protein-coupled pathway requiring p21ras and p74raf-1. J Biol Chem (1993) 1.79
Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol Cell Biol (1999) 1.77
Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv (1996) 1.74
A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras. J Biol Chem (1993) 1.74
Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res (1994) 1.71
Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol (1996) 1.69
A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J (1994) 1.68
A transforming gene present in human sarcoma cell lines. Nature (1982) 1.67
Biochemical and biological properties of the human N-ras p21 protein. Mol Cell Biol (1987) 1.65
PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. Oncogene (2012) 1.63
Evaluation of the API 20C for identification of yeasts. Am J Clin Pathol (1977) 1.62
Mechanism of activation of an N-ras gene in the human fibrosarcoma cell line HT1080. EMBO J (1984) 1.56
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer (2010) 1.56
Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene (1991) 1.54
Scrape-loading of Swiss 3T3 cells with ras protein rapidly activates protein kinase C in the absence of phosphoinositide hydrolysis. Oncogene (1989) 1.50
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene (2007) 1.49
Fluorescence in situ hybridization deletion mapping at 4p16.3 in bladder cancer cell lines refines the localisation of the critical interval to 30 kb. Genes Chromosomes Cancer (1996) 1.47
The sevenmaker gain-of-function mutation in p42 MAP kinase leads to enhanced signalling and reduced sensitivity to dual specificity phosphatase action. FEBS Lett (1994) 1.47
Transformation and stimulation of DNA synthesis in NIH-3T3 cells are a titratable function of normal p21N-ras expression. EMBO J (1986) 1.46
The influence of the MAPK pathway on T cell lineage commitment. Immunity (1997) 1.43
The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis. Arthritis Rheum (1987) 1.41
Cellular response to cancer chemopreventive agents: contribution of the antioxidant responsive element to the adaptive response to oxidative and chemical stress. Biochem Soc Symp (1999) 1.41
Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr Biol (1997) 1.41
Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene (1999) 1.41
CLINICAL EXPERIENCES WITH PERCAIN, A NEW LOCAL ANAESTHETIC. Br Med J (1930) 1.40
Activation of c-Ha-ras-1 proto-oncogene by in vitro modification with a chemical carcinogen, benzo(a)pyrene diol-epoxide. Nature (1984) 1.40
Testosterone metabolism in the rat ventral prostate. Biochem J (1968) 1.39
Cost savings controversy. J Ophthalmic Nurs Technol (1991) 1.39
The urease ELISA for H-Y antibody. A cautionary tale. J Immunol Methods (1990) 1.38
Maintenance of long-term potentiation in rat dentate gyrus requires protein synthesis but not messenger RNA synthesis immediately post-tetanization. Neuroscience (1989) 1.37
Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol Cell Biol (2001) 1.37
Mutant but not normal p21 ras elevates inositol phospholipid breakdown in two different cell systems. Oncogene (1988) 1.37
Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol (1999) 1.37
p21H-ras-induced morphological transformation and increases in c-myc expression are independent of functional protein kinase C. EMBO J (1989) 1.36
Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res (1996) 1.35
A study of ras gene mutations in colonic adenomas from familial polyposis coli patients. Oncogene (1988) 1.35
Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer (1991) 1.33
A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. Nucleic Acids Res (1986) 1.33
p21ras couples the T cell antigen receptor to extracellular signal-regulated kinase 2 in T lymphocytes. J Exp Med (1993) 1.32
Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function. Mol Cell Biol (1993) 1.31
Activation of N-ras in a human melanoma cell line. Mol Cell Biol (1985) 1.30
p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet (1995) 1.30
Mutations activating human c-Ha-ras1 protooncogene (HRAS1) induced by chemical carcinogens and depurination. Proc Natl Acad Sci U S A (1986) 1.29
DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene (1997) 1.29
Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene (1991) 1.27
Stimulation of phosphatidylcholine hydrolysis, diacylglycerol release, and arachidonic acid production by oncogenic ras is a consequence of protein kinase C activation. J Biol Chem (1989) 1.26
Localization of a dermatan sulfate proteoglycan (DS-PGII) in cartilage and the presence of an immunologically related species in other tissues. J Histochem Cytochem (1986) 1.26
Inheritance of proliferative breast disease in breast cancer kindreds. Science (1990) 1.24
Somatic mutation of PTEN in bladder carcinoma. Br J Cancer (1999) 1.24
Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene (1993) 1.23
Activation of the Ral and phosphatidylinositol 3' kinase signaling pathways by the ras-related protein TC21. Mol Cell Biol (2001) 1.23
Signal transduction. Hot lips and phosphorylation of protein kinases. Nature (1994) 1.23
Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene (2007) 1.22
Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics (1998) 1.21
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene (2009) 1.20